Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

NCT02330276
View directory record Official record
Conditions
Pre-diabetes
Interventions
(+)-Epicatechin
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
21 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

NCT01794000
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation

NCT04229992
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Magnesium glycinate, Placebo
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol on Exercise Performance in Fontan Patients

NCT02946892
View directory record Official record
Conditions
Single Ventricle, Fontan
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

NCT06400511
View directory record Official record
Conditions
Blepharitis
Interventions
Pimecrolimus 0.3% Ophthalmic Ointment, Placebo Ophthalmic Ointment
Drug
Lead sponsor
Famy Life Sciences, a Viatris Company
Industry
Eligibility
2 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
29
States / cities
Pheonix, Arizona • Garden Grove, California • Glendale, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Litchfield Park, Arizona • Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

NVA237 Versus Placebo 12-week Efficacy Study

NCT01709864
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
54
States / cities
Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

NCT00071409
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
INGAP-Peptide, placebo
Drug
Lead sponsor
Exsulin Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Irvine, California • San Diego, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Not applicable Interventional

Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms

NCT03826563
View directory record Official record
Conditions
Psychosis, Sleep
Interventions
oral melatonin tablets (NatureMade brand), Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
11 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Not applicable Interventional Results available

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

NCT01337687
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 30, 2026, 11:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

NCT00243243
View directory record Official record
Conditions
Burns
Interventions
Recombinant Factor VIIa, Placebo
Drug
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis

NCT02958917
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Pirfenidone, Placebo controlled
Drug · Other
Lead sponsor
Evans Fernandez Perez
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 30, 2026, 11:50 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

NCT05085197
View directory record Official record
Conditions
Healthy
Interventions
STSA-1005 injection, Placebo
Drug
Lead sponsor
Staidson Biopharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity Treatment Enhanced With Working Memory Training

NCT02529397
View directory record Official record
Conditions
ADHD, Weight Loss
Interventions
Adaptive Working Memory Training, Non-adaptive cognitive training
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

NCT04519697
View directory record Official record
Conditions
Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

NCT04024813
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Seladelpar, Placebo to match Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 30, 2026, 11:50 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT07486960
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Sun City, Arizona • Tucson, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

NCT00056160
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
44
States / cities
Hoover, Alabama • Duarte, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 30, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 30, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

NCT03600480
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Semaglutide, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 30, 2026, 11:50 AM EDT